Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lubsen

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Annals of Internal Medicine|October 1, 1995
Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patientsA W Hoes, D E Grobbee, J Lubsen, et al.
Journal of the American College of Cardiology|July 1, 1986
Relative value of clinical variables, bicycle ergometry, rest radionuclide ventriculography and 24 hour ambulatory electrocardiographic monitoring at discharge to predict 1 year survival after myocardial infarctionP Fioretti, R W Brower, M L Simoons, et al.
European Heart Journal|September 22, 1998
Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Gastro-Intestinal Therapeutic SystemJ Lubsen, P A Poole-Wilson, S J Pocock, et al.
Journal of the American College of Cardiology|January 1, 1991
Reasons for the lack of benefit of immediate angioplasty during recombinant tissue plasminogen activator therapy for acute myocardial infarction: a regional wall motion analysis. European Cooperative Study GroupA E Arnold, P W Serruys, W Rutsch, et al.
Journal of the American College of Cardiology|September 1, 1989
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PAA E Arnold, R W Brower, D Collen, et al.
British Heart Journal|April 1, 1987
Prognostic value of predischarge 12 lead electrocardiogram after myocardial infarction compared with other routine clinical variablesP Fioretti, J G Tijssen, A J Azar, et al.
European Heart Journal|March 1, 1993
Prediction of mortality following hospital discharge after thrombolysis for acute myocardial infarction: is there a need for coronary angiography? European Cooperative Study GroupA E Arnold, M L Simoons, J M Detry, et al.
British Heart Journal|September 1, 1984
Prediction of mortality in hospital survivors of myocardial infarction. Comparison of predischarge exercise testing and radionuclide ventriculography at restP Fioretti, R W Brower, M L Simoons, et al.
Lancet (London, England)|April 13, 1985
Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen ActivatorM Verstraete, R Bernard, M Bory, et al.
Circulation|July 1, 1992
Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study GroupA E Arnold, M L Simoons, F Van de Werf, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Annals of Internal Medicine|October 1, 1995
Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patientsA W Hoes, D E Grobbee, J Lubsen, et al.
Journal of the American College of Cardiology|July 1, 1986
Relative value of clinical variables, bicycle ergometry, rest radionuclide ventriculography and 24 hour ambulatory electrocardiographic monitoring at discharge to predict 1 year survival after myocardial infarctionP Fioretti, R W Brower, M L Simoons, et al.
European Heart Journal|September 22, 1998
Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Gastro-Intestinal Therapeutic SystemJ Lubsen, P A Poole-Wilson, S J Pocock, et al.
Journal of the American College of Cardiology|January 1, 1991
Reasons for the lack of benefit of immediate angioplasty during recombinant tissue plasminogen activator therapy for acute myocardial infarction: a regional wall motion analysis. European Cooperative Study GroupA E Arnold, P W Serruys, W Rutsch, et al.
Journal of the American College of Cardiology|September 1, 1989
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PAA E Arnold, R W Brower, D Collen, et al.
British Heart Journal|April 1, 1987
Prognostic value of predischarge 12 lead electrocardiogram after myocardial infarction compared with other routine clinical variablesP Fioretti, J G Tijssen, A J Azar, et al.
European Heart Journal|March 1, 1993
Prediction of mortality following hospital discharge after thrombolysis for acute myocardial infarction: is there a need for coronary angiography? European Cooperative Study GroupA E Arnold, M L Simoons, J M Detry, et al.
British Heart Journal|September 1, 1984
Prediction of mortality in hospital survivors of myocardial infarction. Comparison of predischarge exercise testing and radionuclide ventriculography at restP Fioretti, R W Brower, M L Simoons, et al.
Lancet (London, England)|April 13, 1985
Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen ActivatorM Verstraete, R Bernard, M Bory, et al.
Circulation|July 1, 1992
Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study GroupA E Arnold, M L Simoons, F Van de Werf, et al.
Pageof 11